Skip to main content
Medical information Clinical review pending

Genetic Testing

SFTPA1 Gene Pulmonary Fibrosis Idiopathic Genetic Test

Genetic test for mutations in the SFTPA1 gene associated with idiopathic pulmonary fibrosis. Helps assess risk and inform management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or Saliva sample. Confirm specific requirements with the laboratory before booking.
Results
3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
A clinical history of the patient is required. Genetic counseling is recommended to establish a family pedigree chart.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the SFTPA1 Gene Pulmonary Fibrosis Idiopathic Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Family history of pulmonary fibrosis
  • ✓Symptoms suggestive of pulmonary fibrosis (e.g., persistent cough, shortness of breath)
  • ✓Unexplained fatigue
  • ✓Assessment of genetic risk for IPF
  • ✓Guiding personalized treatment strategies
02

In plain language

What this test helps you understand

Identifies genetic mutations in the SFTPA1 gene associated with idiopathic pulmonary fibrosis, aiding in risk assessment and personalized management.
The SFTPA1 Gene Pulmonary Fibrosis Idiopathic NGS Genetic DNA Test is a diagnostic tool to identify genetic mutations linked to idiopathic pulmonary fibrosis (IPF). Using Next Generation Sequencing (NGS), this test analyzes the SFTPA1 gene, which is important for lung health. Understanding your genetic risk for IPF can aid in early detection, management, and personalized treatment strategies. This test measures specific mutations within the SFTPA1 gene. Identifying these mutations helps healthcare providers evaluate the likelihood of developing pulmonary fibrosis, a condition involving lung scarring. Individuals with a family history of pulmonary fibrosis, or those experiencing symptoms like persistent cough, shortness of breath, or fatigue, may benefit from this test. Other risk factors include exposure to environmental toxins, smoking history, and age over 50. Benefits include early detection of genetic predisposition, informed treatment decisions, personalized management plans, and peace of mind. Results are typically available within 3 to 4 weeks and should be discussed with a healthcare provider for interpretation and follow-up.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history of the patient is required. Genetic counseling is recommended to establish a family pedigree chart.
SampleBlood sample (EDTA tube) or Saliva sample. Confirm specific requirements with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) analysis of the SFTPA1 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test only analyzes the SFTPA1 gene. Other genes and environmental factors can also contribute to pulmonary fibrosis. A negative result does not completely rule out the condition. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

IPF is a chronic lung disease characterized by progressive scarring of lung tissue, leading to breathing difficulties. Its cause is often unknown (idiopathic).
Individuals with a family history of pulmonary fibrosis or those experiencing symptoms like persistent cough, shortness of breath, or unexplained fatigue should discuss this test with their doctor.
Results should be interpreted by a qualified healthcare provider, often in conjunction with genetic counseling, to understand their significance and implications for your health.
The SFTPA1 gene provides instructions for making a protein called surfactant protein A, which is important for lung function and protecting the lungs from infection and injury.
Genetic counseling is highly recommended before and after testing to help understand the test, its potential results, and their implications for you and your family.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp